MEDICUS PHARMA LTD. Operating Expenses
MEDICUS PHARMA LTD. (MDCX) reported Operating Expenses of $11.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- MEDICUS PHARMA LTD. operating expenses for the quarter ending 2026-06-30 was $11.48M, a 90.80% increase year-over-year.
- MEDICUS PHARMA LTD. operating expenses for the quarter ending 2026-03-31 was $8.60M, a 67.71% increase year-over-year.
- MEDICUS PHARMA LTD. operating expenses for the quarter ending 2025-12-31 was $7.79M, a 117.28% increase year-over-year.
- MEDICUS PHARMA LTD. operating expenses for the quarter ending 2025-09-30 was $15.00, a 100.00% decline year-over-year.
- MEDICUS PHARMA LTD. operating expenses for fiscal 2025 was $34.36M, a 207.30% increase from fiscal 2024.
- MEDICUS PHARMA LTD. operating expenses for fiscal 2024 was $11.18M, a 136.39% increase from fiscal 2023.
- MEDICUS PHARMA LTD. operating expenses for fiscal 2023 was $4.73M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.48M 10-Q · filed 2026-08-12 | $20.08M 10-Q · filed 2026-08-12 | $27.87M derived: sum of 3 quarters · filed 2026-08-12 | $27.87M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $8.60M 10-Q · filed 2026-05-14 | $16.39M derived: sum of 2 quarters · filed 2026-05-14 | $16.39M derived: sum of 3 quarters · filed 2026-05-14 | $22.40M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $7.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $7.79M derived: sum of 2 quarters · filed 2026-03-25 | $13.81M derived: sum of 3 quarters · filed 2026-08-12 | $34.36M 10-K · filed 2026-03-25 |
| 2025-09-30 | $15.00 10-Q · filed 2025-11-14 | $6.02M derived: sum of 2 quarters · filed 2026-08-12 | $26.57M 10-Q · filed 2025-11-14 | $14.73M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $6.02M 10-Q · filed 2026-08-12 | $11.14M 10-Q · filed 2026-08-12 | $14.73M derived: sum of 3 quarters · filed 2026-08-12 | $17.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $5.13M 10-Q · filed 2026-05-14 | $8.71M derived: sum of 2 quarters · filed 2026-05-14 | $11.05M derived: sum of 3 quarters · filed 2026-05-14 | $14.60M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $5.92M derived: sum of 2 quarters · filed 2026-03-25 | $9.47M derived: sum of 3 quarters · filed 2026-03-25 | $11.18M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.33M 10-Q · filed 2025-11-14 | $5.89M derived: sum of 2 quarters · filed 2025-11-14 | $7.60M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $3.55M 10-Q · filed 2025-08-11 | $5.26M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $1.71M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $4.73M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |